Aquestive Therapeutics (NASDAQ:AQST) Given “Market Outperform” Rating at JMP Securities

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research note issued on Monday, Benzinga reports. They currently have a $9.00 price objective on the stock. JMP Securities’ price target would suggest a potential upside of 80.36% from the stock’s current price.

AQST has been the subject of several other reports. HC Wainwright upped their target price on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Monday. Leerink Partners reaffirmed an “outperform” rating and set a $12.00 target price (up from $10.00) on shares of Aquestive Therapeutics in a research report on Monday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.67.

Aquestive Therapeutics Price Performance

NASDAQ AQST traded up $0.27 during mid-day trading on Monday, hitting $4.99. The company’s stock had a trading volume of 217,932 shares, compared to its average volume of 1,799,354. The firm has a market capitalization of $454.28 million, a P/E ratio of -11.88 and a beta of 2.84. Aquestive Therapeutics has a 52-week low of $1.25 and a 52-week high of $6.23. The stock’s fifty day simple moving average is $4.22 and its two-hundred day simple moving average is $3.70.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Tuesday, August 6th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.08. The business had revenue of $20.10 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the business posted ($0.10) EPS. On average, equities analysts forecast that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $27,000. PFG Investments LLC lifted its position in shares of Aquestive Therapeutics by 22.9% in the 2nd quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock worth $153,000 after buying an additional 11,000 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter valued at about $54,000. Financial Advocates Investment Management grew its position in shares of Aquestive Therapeutics by 70.0% during the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after buying an additional 14,000 shares during the last quarter. Finally, Lazard Asset Management LLC raised its stake in Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the period. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.